How to Evaluate Biospecimen and Lab Testing Services for Translational Research

June 11, 2026

Biomarker-driven diagnostics and therapeutics depend on one critical factor: the quality of the samples and data used to generate evidence.
Whether you're developing a companion diagnostic, validating a new assay, or advancing a therapeutic program, choosing the right provider for biospecimen and lab testing services can significantly impact timelines, data quality, and regulatory outcomes.
Many organizations manage sample procurement and laboratory testing through separate vendors. While this approach may seem flexible, it often introduces operational complexity, increases chain-of-custody risks, and creates delays when projects require rapid adaptation.
An integrated provider that combines sample procurement, CLIA-certified testing, and project management can simplify operations while improving study consistency.
Here are seven factors every pharma and IVD team should evaluate when selecting a partner.

1. Verify CLIA Certification and Laboratory Accreditation

The first question should be straightforward:

Is the laboratory CLIA-certified and CAP-accredited?

These certifications demonstrate adherence to rigorous quality standards and provide confidence that testing processes are performed under controlled and validated conditions.
A laboratory operating under CLIA and CAP standards can help support:
• Method comparison studies
• Assay validation projects
• Biomarker analysis
• Clinical trial testing
For organizations preparing FDA submissions or clinical validation studies, accredited laboratory infrastructure is often a non-negotiable requirement. Boca Bio operates a CLIA-certified and CAP-accredited laboratory that supports diagnostic and drug development programs.

2. Assess Biospecimen Access and Procurement Capabilities

Laboratory expertise is only valuable if the provider can consistently source the specimens your study requires.
Ask potential partners:
• Can they access challenging populations?
• Do they support prospective collections?
• Do they provide matched healthy controls?
• Can they source multiple specimen types?
High-quality research biospecimens should include detailed clinical metadata and clear documentation regarding collection, processing, and storage procedures.
Boca Bio maintains access to more than one million characterized specimens and supports custom procurement across multiple therapeutic areas, including oncology, infectious disease, immunology, neurology, and cardiometabolic research.

3. Evaluate Biomarker Testing Expertise

Not all laboratories are designed for biomarker research.
When assessing providers, determine whether they can support:
• Flexibility
• Adaptability to last-minute changes
• Method comparison studies
• Biomarker validation
• Multi-platform testing
A strong biomarker partner should offer flexibility to onboard new assays and adapt testing strategies as projects evolve.
This becomes particularly important when studies require validation across multiple technologies or support regulatory submissions. Boca Bio's central laboratory supports molecular and immunological testing across a broad range of analyzers and assay platforms.

4. Look for Integrated Laboratory Services

One of the most overlooked evaluation criteria is operational integration.
Working with separate vendors for:
• Sample procurement
• Laboratory testing
• Biostorage
• Data management
can create unnecessary complexity.

Integrated laboratory services provide:

5. Examine Regulatory Support Experience

Regulatory studies often require more than laboratory testing.
Ask providers whether they have experience supporting:

• FDA 510(k) submissions
• Method comparison studies
• Clinical validation studies
• Companion diagnostic development
• Longitudinal sample collections

Partners with regulatory experience can identify potential issues earlier and help maintain study momentum.

For example, Boca Bio has supported numerous women's health and respiratory assay benchmarking studies designed to generate clinical data for FDA submissions within a CLIA-accredited, CAP-certified laboratory environment

6. Assess Data Management and Traceability

7. Evaluate Speed and Flexibility

Timelines can make or break clinical and diagnostic development programs.
The best clinical testing providers combine scientific rigor with operational agility.
Look for evidence that the organization can:

• Adapt to changing study requirements
• Accelerate site activation
• Scale sample procurement quickly
• Respond rapidly to sponsor requests

Case studies can provide valuable insight into how vendors perform under real-world conditions. Boca Bio has supported projects involving accelerated sample procurement, rapid site activation, assay validation, and time-sensitive FDA-related studies.

Questions to Ask Potential Biomarker Testing Partners

Before selecting a provider, consider asking:

1. Is your laboratory CLIA-certified and CAP-accredited?
2. Can you provide both biospecimen procurement and testing services?
3. What therapeutic areas do you support?
4. How do you ensure sample traceability?
5. Can you support FDA submission studies?
6. What biomarker analysis platforms are available?
7. How quickly can you initiate new projects?
8. Do you provide project management support?

The answers can quickly reveal whether a provider is positioned to support both your immediate study requirements and long-term development goals.

Why Integrated Biospecimen and Lab Testing Services Matter

As biomarker-driven research becomes increasingly complex, organizations benefit from working with partners that can manage procurement, testing, storage, and data management under one quality framework.

An integrated approach reduces operational friction, improves consistency, and helps research teams focus on generating meaningful scientific insights rather than coordinating multiple vendors.

For pharma and IVD developers, selecting the right partner is not simply about obtaining samples or running tests—it's about building a foundation for reliable data, faster decisions, and successful program outcomes.

Contact Us

Bullet Point List Lorem ipsum dolor

Lorem ipsum dolor sit amet

Fusce tristique lorem non justo malesuada, et ullamcorper risus volutpat

Cras fringilla urna vel metus lobortis, eget egestas nulla efficias fringilla urna vel mngilla urna vel metus lobortis, eget egestas nulla efficias fringilla urna vel metus lobortie